I've charted the available Phase II trials data for Bisantrene (RAC) and PTX-200 (PTX).
Sources:
- Marty M, et al. Cancer Treat Rep. 1985;69:703-705. 2. Marty M, et al. Fourth International Symposium on
- Therapy of Acute Leukemia. Series Bisantrene: an anthracycline derivative active in ANLL: Phase 2 Study. Rome, Italy; 1987. Abstr. 598.
- Leblanc T, et al. Med Pediatr Oncol. 1994;22:119-124.
- Tosi P, et al. Haematologica. 1989;74:555-558.
- Bezwoda WR, Seymour L. Bone Marrow Transplant. 1989;4(suppl 3): 65.
- Spadea A, et al. Leuk Lymphoma 1993;9:217-220.
- https://www.asx.com.au/asxpdf/20191127/pdf/44c022j20vm3j9.pdf
1993: 5 of a total of 7 (72%) patients achieved total eradication of their cancer (R/R AML), page-18
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.025(2.16%) |
Mkt cap ! $200.6M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.20 | $1.15 | $19.66K | 16.90K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 556 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 3826 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2025 (20 minute delay) ? |
| RAC (ASX) Chart |